Trending NewsTrending NewsNYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $60.51 +1.23 (+2.07%) Closing price 10/15/2026 03:59 PM EasternExtended Trading$60.69 +0.18 (+0.30%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$60.39▼$62.2550-Day Range$56.73▼$68.0652-Week Range$42.52▼$68.64Volume13.75 million shsAverage Volume14.76 million shsMarket Capitalization$123.60 billionP/E Ratio13.33Dividend Yield4.16%Price Target$64.88Consensus RatingHold Company Overview Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets. Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors. Its newer and specialized products include Breyanzi, a cell therapy for certain blood cancers; Camzyos, a cardiovascular medicine; and Sotyktu, an immunology treatment. The company also develops investigational therapies through internal research and collaborations. The company traces its history to the formation of Bristol-Myers in 1889 and the founding of the E.R. Squibb & Sons pharmaceutical business in 1858. Bristol-Myers Squibb was created through the 1989 merger of the two companies. Its corporate headquarters are in Princeton, New Jersey. Christopher Boerner has served as chief executive officer since November 2023.AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreBMY MarketRank™: 4.59942211715 of 5 starsBristol Myers Squibb scored higher than 92% of companies evaluated by MarketBeat, and ranked 41st out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingHold Consensus RatingBristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 2 strong buy ratings, 11 buy ratings, 16 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 25 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-1.80% Earnings GrowthEarnings for Bristol Myers Squibb are expected to decrease by -1.80% in the coming year, from $6.65 to $6.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 13.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 36.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 13.33, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 209.00.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.30. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bristol Myers Squibb's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 3.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bristol Myers Squibb has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.45%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 55.51%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 38.59% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media3.5 / 5News Sentiment0.62 News SentimentBristol Myers Squibb has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 67 news articles for Bristol Myers Squibb this week, compared to 9 articles on an average week.Search Interest49 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows35 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 192% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,750.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News HeadlinesBMY - Bristol-Myers Squibb CompanyOctober 15 at 2:06 PM | seekingalpha.comNeuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsightOctober 15 at 2:06 PM | finance.yahoo.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) InvestorsOctober 15 at 2:06 PM | finance.yahoo.comBristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS SaysOctober 15 at 2:06 PM | finance.yahoo.comBristol Myers Squibb Gains 4.1% in a Single Session, Adding ~$5 BillionOctober 14 at 11:52 PM | 247wallst.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lemaitre Vascular (LMAT) and Bristol-Myers Squibb (BMY)October 14 at 1:51 PM | theglobeandmail.comBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItOctober 14 at 1:51 PM | finance.yahoo.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 on January 1st, 2026. Since then, BMY shares have increased by 12.2% and is now trading at $60.5060. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) issued its quarterly earnings data on Thursday, July, 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The company's revenue for the quarter was up 5.7% on a year-over-year basis. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Shares of Bristol Myers Squibb split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others. Who are Bristol Myers Squibb's major shareholders? Top institutional investors of Bristol Myers Squibb include Artemis Investment Management LLP (0.14%), Fort Washington Investment Advisors Inc. OH (0.08%), Douglas Lane & Associates LLC (0.07%) and Mn Services Vermogensbeheer B.V. (0.03%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Phil M Holzer, Benjamin Hickey and Bartie Wendy Short. View institutional ownership trends. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include NVIDIA (NVDA), Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), AT&T (T) and Verizon Communications (VZ). Company Calendar Record date for 8/3 Dividend7/02/2026Ex-Dividend for 8/3 Dividend7/02/2026Last Earnings7/30/2026Dividend Payable8/03/2026Record date for 11/2 Dividend10/02/2026Ex-Dividend for 11/2 Dividend10/02/2026Today10/16/2026Next Earnings (Estimated)10/29/2026Dividend Payable11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, BMY's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(609) 252-4621Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$64.88 High Price Target$76.00 Low Price Target$41.00 Potential Upside/Downside+7.2%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$4.54 Trailing P/E Ratio13.33 Forward P/E Ratio9.10 P/E Growth0.3Net Income$7.05 billion Net Margins18.87% Pretax Margin24.21% Return on Equity66.90% Return on Assets14.74% Debt Debt-to-Equity Ratio1.89 Current Ratio1.53 Quick Ratio1.38 Sales & Book Value Annual Sales$49.19 billion Price / Sales2.51 Cash Flow$8.30 per share Price / Cash Flow7.29 Book Value$9.09 per share Price / Book6.66Miscellaneous Outstanding Shares2,042,715,000Free Float2,041,694,000Market Cap$123.60 billion OptionableOptionable Beta0.19 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSE:BMY) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...Investors Alley | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
